Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17747
Country/Region: Nigeria
Year: 2018
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $0 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Prevention: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD 10-14, Female, Physical and/or Emotional Violence 2019 10
GEND_GBV_DSD 10-14, Female, Sexual Violence (Post-Rape Care) 2019 10
GEND_GBV_DSD 10-14, Male, Physical and/or Emotional Violence 2019 2
GEND_GBV_DSD 10-14, Male, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV_DSD 15-19, Female, Physical and/or Emotional Violence 2019 11
GEND_GBV_DSD 15-19, Female, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV_DSD 15-19, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV_DSD 15-19, Male, Sexual Violence (Post-Rape Care) 2019 8
GEND_GBV_DSD 20-24, Female, Physical and/or Emotional Violence 2019 20
GEND_GBV_DSD 20-24, Female, Sexual Violence (Post-Rape Care) 2019 50
GEND_GBV_DSD 20-24, Male, Physical and/or Emotional Violence 2019 4
GEND_GBV_DSD 20-24, Male, Sexual Violence (Post-Rape Care) 2019 27
GEND_GBV_DSD 50+, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV_DSD 50+, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV_DSD <10, Female, Physical and/or Emotional Violence 2019 7
GEND_GBV_DSD <10, Female, Sexual Violence (Post-Rape Care) 2019 8
GEND_GBV_DSD <10, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV_DSD <10, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2019 138
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 177
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2019 153
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care) 2019 12
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence 2019 16
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence 2019 17
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care) 2019 5
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence 2019 6
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence 2019 13
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence 2019 5
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence 2019 13
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence 2019 5
GEND_GBV_DSD GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV_DSD Number of people receiving post-GBV care 2019 330
HTC_TST_DSD By Key Population: FSW, Negative 2019 4,181
HTC_TST_DSD By Key Population: FSW, Positive 2019 137
HTC_TST_DSD By Key Population: MSM, Negative 2019 4,408
HTC_TST_DSD By Key Population: MSM, Positive 2019 554
HTC_TST_DSD By Key Population: PWID, Negative 2019 1,996
HTC_TST_DSD By Key Population: PWID, Positive 2019 25
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative 2019 5
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative 2019 5
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative 2019 3
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative 2019 3
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative 2019 1
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative 2019 4
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative 2019 12
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive 2019 1
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative 2019 7
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative 2019 18
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive 2019 1
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative 2019 17
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative 2019 12
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive 2019 1
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative 2019 22
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive 2019 1
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative 2019 17
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive 2019 1
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative 2019 12
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive 2019 3
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative 2019 3
HTC_TST_DSD HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative 2019 1
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative 2019 77
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive 2019 29
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative 2019 38
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive 2019 34
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative 2019 61
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive 2019 24
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative 2019 115
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive 2019 15
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative 2019 100
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive 2019 22
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative 2019 107
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive 2019 39
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative 2019 92
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive 2019 24
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative 2019 84
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive 2019 29
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative 2019 80
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative 2019 30
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative 2019 91
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive 2019 8
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative 2019 91
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive 2019 2
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative 2019 70
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive 2019 17
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative 2019 141
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative 2019 121
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive 2019 6
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative 2019 40
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive 2019 16
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative 2019 839
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive 2019 71
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative 2019 1,259
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive 2019 149
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative 2019 629
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive 2019 35
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative 2019 839
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive 2019 42
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative 2019 105
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive 2019 7
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative 2019 105
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive 2019 35
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative 2019 420
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative 2019 420
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative 2019 4,264
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive 2019 170
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative 2019 3,655
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive 2019 191
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative 2019 2,436
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive 2019 255
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative 2019 1,827
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive 2019 106
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative 2019 1,218
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive 2019 213
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative 2019 1,523
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive 2019 128
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative 2019 1,827
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive 2019 319
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative 2019 2,436
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive 2019 170
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative 2019 4,280
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive 2019 54
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative 2019 1,873
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive 2019 34
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative 2019 2,140
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive 2019 47
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative 2019 1,605
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive 2019 11
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive 2019 33
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative 2019 579
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive 2019 33
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative 2019 386
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive 2019 47
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive 2019 38
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative 2019 482
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive 2019 43
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative 2019 321
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive 2019 38
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative 2019 321
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive 2019 38
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative 2019 96
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive 2019 43
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 67,251
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 136
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 107
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 35
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 963
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 57
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 4,158
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 226
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 188
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 293
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 20
HTC_TST_DSD Service Delivery Point (Facility) ANC: 10-14, Negative 2019 9
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Negative 2019 413
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Positive 2019 10
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Negative 2019 2,697
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Positive 2019 63
HTC_TST_DSD Service Delivery Point (Facility) ANC: 50+, Negative 2019 401
HTC_TST_DSD Service Delivery Point (Facility) ANC: 50+, Positive 2019 7
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Negative 2019 63
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 8
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 9
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 8
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 16
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 16
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 8
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 15
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 31
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 22
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 339
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 6
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 87
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 77
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 36
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 30
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 86
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 88
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 49
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 9
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 50
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 8
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,459
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 64
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 525
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 15
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 590
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 11
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,091
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 30
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 914
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 89
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 2,977
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 111
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 3,577
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 170
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 1,003
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 65
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,610
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 106
HTC_TST_DSD Service Delivery Point (Facility) VCT: 1-9, Negative 2019 389
HTC_TST_DSD Service Delivery Point (Facility) VCT: 1-9, Positive 2019 22
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 121
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 10
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 190
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 6
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 104
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 59
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 340
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 52
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 207
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 43
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 124
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 28
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 198
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 29
HTS_SELF_DSD HTS_SELF_N_DSD 2019 20
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted 2019 10
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTest Unassisted 2019 10
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self 2019 2
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner 2019 2
HTS_SELF_DSD HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted 2019 1
HTS_SELF_DSD HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted 2019 1
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 3,857
KP_PREV_DSD By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 1,836
KP_PREV_DSD By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 18,083
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 23,776
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2019 621
PMTCT_ART_DSD New on ART 2019 180
PMTCT_ART_DSD Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 801
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 14,222
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2019 610
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2019 152
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 762
PMTCT_EID_DSD Sum of Infant Age disaggregates 2019 762
PMTCT_STAT_DSD By Age (Denominator): 10-14 2019 28
PMTCT_STAT_DSD By Age (Denominator): 20-24 2019 2,895
PMTCT_STAT_DSD By Age (Denominator): 50+ 2019 75
PMTCT_STAT_DSD By Age (Denominator): <15-19 2019 450
PMTCT_STAT_DSD By Age (Numerator): 10-14 2019 27
PMTCT_STAT_DSD By Age (Numerator): 15-19 2019 428
PMTCT_STAT_DSD By Age (Numerator): 20-24 2019 2,750
PMTCT_STAT_DSD By Age (Numerator): 50+ 2019 71
PMTCT_STAT_DSD By Number of known positives: 10-14 2019 1
PMTCT_STAT_DSD By Number of known positives: 15-19 2019 19
PMTCT_STAT_DSD By Number of known positives: 20-24 2019 126
PMTCT_STAT_DSD By Number of known positives: 50+ 2019 3
PMTCT_STAT_DSD By Number of new negative: 10-14 2019 45
PMTCT_STAT_DSD By Number of new negative: 15-19 2019 402
PMTCT_STAT_DSD By Number of new negative: 20-24 2019 2,587
PMTCT_STAT_DSD By Number of new negative: 50+ 2019 67
PMTCT_STAT_DSD By Number of new positives: 15-19 2019 7
PMTCT_STAT_DSD By Number of new positives: 20-24 2019 38
PMTCT_STAT_DSD By Number of new positives: 50+ 2019 1
PMTCT_STAT_DSD Number of new ANC and L&D clients 2019 15,007
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 14,222
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 25-29, Female 2019 5,753
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 30-34, Female 2019 3,910
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 35-39, Female 2019 1,565
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 40-49, Female 2019 331
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 25-29, Female 2019 5,465
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 30-34, Female 2019 3,715
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 35-39, Female 2019 1,486
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 40-49, Female 2019 314
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive 2019 239
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative 2019 5,140
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive 2019 96
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive 2019 182
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative 2019 3,494
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive 2019 55
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive 2019 80
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative 2019 1,398
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive 2019 33
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive 2019 10
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative 2019 296
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive 2019 5
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 216
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 98
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 315
TB_PREV_DSD By Age/Sex (Denominator): 15+, Female 2019 15,352
TB_PREV_DSD By Age/Sex (Denominator): 15+, Male 2019 5,258
TB_PREV_DSD By Age/Sex (Denominator): <15, Female 2019 158
TB_PREV_DSD By Age/Sex (Denominator): <15, Male 2019 53
TB_PREV_DSD By Age/Sex (Numerator): 15+, Female 2019 11,961
TB_PREV_DSD By Age/Sex (Numerator): 15+, Male 2019 5,980
TB_PREV_DSD By Age/Sex (Numerator): <15, Female 2019 598
TB_PREV_DSD By Age/Sex (Numerator): <15, Male 2019 199
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 19,779
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 1,041
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 17,802
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 938
TB_PREV_DSD The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 18,738
TB_PREV_DSD The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 20,820
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 311
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 311
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 34
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 34
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 523
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 523
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 22
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 22
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 890
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2019 890
TX_CURR_DSD Age/Sex: 10-14 Female 2019 269
TX_CURR_DSD Age/Sex: 10-14 Male 2019 286
TX_CURR_DSD Age/Sex: 15-19 Female 2019 179
TX_CURR_DSD Age/Sex: 15-19 Male 2019 208
TX_CURR_DSD Age/Sex: 20-24 Female 2019 579
TX_CURR_DSD Age/Sex: 20-24 Male 2019 651
TX_CURR_DSD Age/Sex: 50+ Female 2019 2,412
TX_CURR_DSD Age/Sex: 50+ Male 2019 2,724
TX_CURR_DSD Age/Sex: <1 2019 16
TX_CURR_DSD Age/Sex: <1-9 2019 594
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2019 32,156
TX_CURR_DSD Sum of age/sex disaggregates 2019 387
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 2,617
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 1,181
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 4,061
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 1,265
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 4,219
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 1,788
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 5,300
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 3,808
TX_NEW_DSD Breastfeeding status 2019 12
TX_NEW_DSD By Age/Sex: 1-9 2019 99
TX_NEW_DSD By Age/Sex: 10-14 Female 2019 16
TX_NEW_DSD By Age/Sex: 10-14 Male 2019 5
TX_NEW_DSD By Age/Sex: 15-19 Female 2019 218
TX_NEW_DSD By Age/Sex: 20-24 Female 2019 340
TX_NEW_DSD By Age/Sex: 20-24 Male 2019 82
TX_NEW_DSD By Age/Sex: 50+ Female 2019 177
TX_NEW_DSD By Age/Sex: 50+ Male 2019 150
TX_NEW_DSD By Age/Sex: <1 2019 26
TX_NEW_DSD By Key populations: People who inject drugs (PWID) 2019 36
TX_NEW_DSD FSW 2019 142
TX_NEW_DSD MSM 2019 391
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 3,697
TX_NEW_DSD Pregnancy status 2019 123
TX_NEW_DSD Sum of Age/Sex disaggregates 2019 988
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 469
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 238
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 295
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 150
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 371
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 188
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 579
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 294
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 20,827
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 492
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 9,224
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 201
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 624
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 17
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 709
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 17
TX_PVLS_DSD Denominator: Indication: Routine 2019 31,384
TX_PVLS_DSD Denominator: Indication: Targeted 2019 727
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 32,111
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,073
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,872
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,563
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,400
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 73
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 66
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 76
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 68
TX_RET_DSD Denominator by Status: Breastfeeding 2019 13
TX_RET_DSD Denominator by Status: Pregnant 2019 131
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 3,407
TX_RET_DSD Numerator by Status: Breastfeeding 2019 12
TX_RET_DSD Numerator by Status: Pregnant 2019 118
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 3,785
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Female 2019 1,071
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Male 2019 1,282
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Female 2019 21,015
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 2019 8,789
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 25,726
TX_TB_DSD Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 25,726
TX_TB_DSD Number of ART patients who were screened for TB at least once during the reporting period 2019 32,156
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive 2019 17,109
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive 2019 2,792
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive 2019 11,405
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive 2019 850